ARTICLE | Clinical News

Emricasan: Phase II started

September 15, 2014 7:00 AM UTC

Conatus began an open-label, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 28 days in about 20 patients with cirrhosis and portal hypertension. Top-line data from the trial are slated for 3Q15. Emricasan is also in a Phase IIb trial to treat acute-on-chronic liver failure (ACLF), with data slated for 4Q14; a Phase IIb trial in post-liver transplant HCV patients with unresolved fibrosis, with interim data expected in 1H15; a Phase II trial to treat liver cirrhosis, with top-line data expected in 2H15; and a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), with data slated for 1Q15. ...